Perspectives on the use of mesenchymal stem cells in vascularized composite allotransplantation

Frontiers in Immunology

Volumn 4, Issue JUL, 2013, Pages

  Plock, Jan A ^a,b   Schnider, Jonas T ^a   Solari, Mario G ^a   Zheng, Xin Xiao ^a,c   Gorantla, Vijay S ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c TONGJI UNIVERSITY   (China)

Author keywords

Adipose stem cells; Cell based therapy; Composite tissue allotransplantation; Immunomodulation; Tolerance

Indexed keywords

CYCLOSPORIN; RAPAMYCIN; TACROLIMUS;

ADAPTIVE IMMUNITY; ALLOTRANSPLANTATION; ARTICLE; CELL CULTURE; CELL HOMING; CHIMERA; GRAFT SURVIVAL; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; IRRADIATION; MESENCHYMAL STEM CELL; NERVE REGENERATION; NONHUMAN; STEM CELL TRANSPLANTATION; VASCULARIZED COMPOSITE ALLOTRANSPLANTATION;

EID: 84883722293     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00175     Document Type: Article

References (89)

1. Petruzzo P, Lanzetta M, Dubernard JM, Landin L, Cavadas P, Margreiter R, et al. The international registry on hand and composite tissue transplantation. Transplantation (2010) 90:1590-4. doi:10.1097/TP.0b013e3181ff1472
2. Petruzzo P, Kanitakis J, Badet L, Pialat JB, Boutroy S, Charpulat R, et al. Long-term follow-up in composite tissue allotransplantation: in-depth study of five (hand and face) recipients. Am J Transplant (2011) 11:808-16. doi:10.1111/j.1600-6143.2011.03469.x
3. Petruzzo P, Testelin S, Kanitakis J, Badet L, Lengele B, Girbon JP, et al. First human face transplantation: 5 years outcomes. Transplantation (2012) 93:236-40. doi:10.1097/TP.0b013e31823d4af6
4. Singer NG, Caplan AI. Mesenchymal stem cells: mechanisms of inflammation. Annu Rev Pathol (2011) 6:457-78. doi:10.1146/annurev-pathol-011110-130230
5. English K. Mechanisms of mesenchymal stromal cell immunomodulation. Immunol Cell Biol (2013) 91:19-26. doi:10.1038/icb.2012.56
6. Izadpanah R, Trygg C, Patel B, Kriedt C, Dufour J, Gimble JM, et al. Biologic properties of mesenchymal stem cells derived from bone marrow and adipose tissue. J Cell Biochem (2006) 99:1285-97. doi:10.1002/jcb.20904
7. Liu TM, Martina M, Hutmacher DW, Hui JH, Lee EH, Lim B. Identification of common pathways mediating differentiation of bone marrow- and adipose tissuederived human mesenchymal stem cells into three mesenchymal lineages. Stem Cells (2007) 25:750-60. doi:10.1634/stemcells.2006-0394
8. Noel D, Caton D, Roche S, Bony C, Lehmann S, Casteilla L, et al. Cell specific differences between human adipose-derived and mesenchymal-stromal cells despite similar differentiation potentials. Exp Cell Res (2008) 314:1575-84. doi:10.1016/j.yexcr.2007.12.022
9. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, Mcintosh K, Patil S, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol (2002) 30:42-8. doi:10.1016/S0301-472X(01)00769-X
10. De Ugarte DA, Morizono K, Elbarbary A, Alfonso Z, Zuk PA, Zhu M, et al. Comparison of multi-lineage cells from human adipose tissue and bone marrow. Cells Tissues Organs (2003) 174:101-9. doi:10.1159/000071150
11. Melief SM, Zwaginga JJ, Fibbe WE, Roelofs H. Adipose tissue-derived multipotent stromal cells have a higher immunomodulatory capacity than their bone marrow-derived counterparts. Stem Cells Transl Med (2013) 2:455-63. doi:10.5966/sctm.2012-0184
12. Cui L, Yin S, Liu W, Li N, Zhang W, Cao Y. Expanded adipose-derived stem cells suppress mixed lymphocyte reaction by secretion of prostaglandin E2. Tissue Eng (2007) 13:1185-95. doi:10.1089/ten.2006.0315
13. Fang B, Song Y, Lin Q, Zhang Y, Cao Y, Zhao RC, et al. Human adipose tissue-derived mesenchymal stromal cells as salvage therapy for treatment of severe refractory acute graft-vs.-host disease in two children. Pediatr Transplant (2007) 11:814-7. doi:10.1111/j.1399-3046.2007.00780.x
14. Wan CD, Cheng R, Wang HB, Liu T. Immunomodulatory effects of mesenchymal stem cells derived from adipose tissues in a rat orthotopic liver transplantation model. Hepatobiliary Pancreat Dis Int (2008) 7:29-33.
15. Constantin G, Marconi S, Rossi B, Angiari S, Calderan L, Anghileri E, et al. Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells (2009) 27:2624-35. doi:10.1002/stem.194
16. Gonzalez MA, Gonzalez-Rey E, Rico L, Buscher D, Delgado M. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum (2009) 60:1006-19. doi:10.1002/art.24405
17. Gonzalez-Rey E, Anderson P, Gonzalez MA, Rico L, Buscher D, Delgado M. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut (2009) 58:929-39. doi:10.1136/gut.2008.168534
18. Crop MJ, Baan CC, Korevaar SS, Ijzermans JN, Pescatori M, Stubbs AP, et al. Inflammatory conditions affect gene expression and function of human adipose tissue-derived mesenchymal stem cells. Clin Exp Immunol (2010) 162:474-86. doi:10.1111/j.1365-2249.2010.04256.x
19. Gonzalez-Rey E, Gonzalez MA, Varela N, O'Valle F, Hernandez-Cortes P, Rico L, et al. Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Ann Rheum Dis (2010) 69:241-8. doi:10.1136/ard.2008.101881
20. Engela AU, Baan CC, Dor FJ, Weimar W, Hoogduijn MJ. On the interactions between mesenchymal stem cells and regulatory T cells for immunomodulation in transplantation. Front Immunol (2012) 3:126. doi:10.3389/fimmu.2012.00126
21. Jones BJ, Mctaggart SJ. Immunosuppression by mesenchymal stromal cells: from culture to clinic. Exp Hematol (2008) 36:733-41. doi:10.1016/j.exphem.2008.03.006
22. Griffin MD, Ritter T, Mahon BP. Immunological aspects of allogeneic mesenchymal stem cell therapies. Hum Gene Ther (2010) 21:1641-55. doi:10.1089/hum.2010.156
23. Parekkadan B, Milwid JM. Mesenchymal stem cells as therapeutics. Annu Rev Biomed Eng (2010) 12:87-117. doi:10.1146/annurev-bioeng-070909-105309
24. Weng JY, Du X, Geng SX, Peng YW, Wang Z, Lu ZS, et al. Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplant (2010) 45:1732-40. doi:10.1038/bmt.2010.195
25. Bernardo ME, Ball LM, Cometa AM, Roelofs H, Zecca M, Avanzini MA, et al. Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation. Bone Marrow Transplant (2011) 46:200-7. doi:10.1038/bmt.2010.87
26. Lee WP, Yaremchuk MJ, Pan YC, Randolph MA, Tan CM, Weiland AJ. Relative antigenicity of components of a vascularized limb allograft. Plast Reconstr Surg (1991) 87:401-11. doi:10.1097/00006534-199103000-00001
27. Djouad F, Charbonnier LM, BouffiC, Louis-Plence P, Bony C, Apparailly F, et al. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells (2007) 25:2025-32. doi:10.1634/stemcells.2006-0548
28. English K, Barry FP, Mahon BP. Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation. Immunol Lett (2008) 115:50-8. doi:10.1016/j.imlet.2007.10.002
29. Li M, Sun K, Welniak LA, Murphy WJ. Immunomodulation and pharmacological strategies in the treatment of graft-versus-host disease. Expert Opin Pharmacother (2008) 9:2305-16. doi:10.1517/14656566.9.13.2305
30. Zhang X, Jiao C, Zhao S. Role of mesenchymal stem cells in immunological rejection of organ transplantation. Stem Cell Rev (2009) 5:402-9. doi:10.1007/s12015-009-9076-y
31. Selmani Z, Naji A, Zidi I, Favier B, Gaiffe E, Obert L, et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells (2008) 26:212-22. doi:10.1634/stemcells.2007-0554
32. De Miguel MP, Fuentes-Julian S, Blazquez-Martinez A, Pascual CY, Aller MA, Arias J, et al. Immunosuppressive properties of mesenchymal stem cells: advances and applications. Curr Mol Med (2012) 12:574-91. doi:10.2174/156652412800619950
33. Nasef A, Mathieu N, Chapel A, Frick J, Francois S, Mazurier C, et al. Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation (2007) 84:231-7. doi:10.1097/01.tp.0000267918.07906.08
34. Selmani Z, Naji A, Gaiffe E, Obert L, Tiberghien P, Rouas-Freiss N, et al. HLA-G is a crucial immunosuppressive molecule secreted by adult human mesenchymal stem cells. Transplantation (2009) 87:S62-6. doi:10.1097/TP.0b013e3181a2a4b3
35. English K, Ryan JM, Tobin L, Murphy MJ, Barry FP, Mahon BP. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin Exp Immunol (2009) 156:149-60. doi:10.1111/j.1365-2249
36. Franquesa M, Hoogduijn MJ, Bestard O, Grinyo JM. Immunomodulatory effect of mesenchymal stem cells on B cells. Front Immunol (2012) 3:212. doi:10.3389/fimmu.2012.00212
37. Liu G, Cheng Y, Guo S, Feng Y, Li Q, Jia H, et al. Transplantation of adipose-derived stem cells for peripheral nerve repair. Int J Mol Med (2011) 28:565-72. doi:10.3892/ijmm.2011.725
38. Lopatina T, Kalinina N, Karagyaur M, Stambolsky D, Rubina K, Revischin A, et al. Adipose-derived stem cells stimulate regeneration of peripheral nerves: BDNF secreted by these cells promotes nerve healing and axon growth de novo. PLoS ONE (2011) 6:e17899. doi:10.1371/journal.pone.0017899
39. Carriel V, Garrido-Gomez J, Hernandez-Cortes P, Garzon I, Garcia-Garcia S, Saez-Moreno JA, et al. Combination of fibrin-agarose hydrogels and adipose-derived mesenchymal stem cells for peripheral nerve regeneration. J Neural Eng (2013) 10:026022. doi:10.1088/1741-2560/10/2/026022
40. Marconi S, Castiglione G, Turano E, Bissolotti G, Angiari S, Farinazzo A, et al. Human adipose-derived mesenchymal stem cells systemically injected promote peripheral nerve regeneration in the mouse model of sciatic crush. Tissue Eng Part A (2012) 18:1264-72. doi:10.1089/ten. TEA.2011.0491
41. Chen CJ, Ou YC, Liao SL, Chen WY, Chen SY, Wu CW, et al. Transplantation of bone marrow stromal cells for peripheral nerve repair. Exp Neurol (2007) 204:443-53. doi:10.1016/j.expneurol.2006.12.004
42. Sbano P, Cuccia A, Mazzanti B, Urbani S, Giusti B, Lapini I, et al. Use of donor bone marrow mesenchymal stem cells for treatment of skin allograft rejection in a preclinical rat model. Arch Dermatol Res (2008) 300:115-24. doi:10.1007/s00403-007-0827-9
43. Solari MG, Srinivasan S, Boumaza I, Unadkat J, Harb G, Garcia-Ocana A, et al. Marginal mass islet transplantation with autologous mesenchymal stem cells promotes long-term islet allograft survival and sustained normoglycemia. J Autoimmun (2009) 32:116-24. doi:10.1016/j.jaut.2009.01.003
44. Wu GD, Nolta JA, Jin YS, Barr ML, Yu H, Starnes VA, et al. Migration of mesenchymal stem cells to heart allografts during chronic rejection. Transplantation (2003) 75:679-85. doi:10.1097/01.TP.0000048488.35010.95
45. Inoue S, Popp FC, Koehl GE, Piso P, Schlitt HJ, Geissler EK, et al. Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation (2006) 81:1589-95. doi:10.1097/01.tp.0000209919.90630.7b
46. Zhou HP, Yi DH, Yu SQ, Sun GC, Cui Q, Zhu HL, et al. Administration of donor-derived mesenchymal stem cells can prolong the survival of rat cardiac allograft. Transplant Proc (2006) 38:3046-51. doi:10.1016/j.transproceed.2006.10.002
47. Itakura S, Asari S, Rawson J, Ito T, Todorov I, Liu CP, et al. Mesenchymal stem cells facilitate the induction of mixed hematopoietic chimerism and islet allograft tolerance without GVHD in the rat. Am J Transplant (2007) 7:336-46. doi:10.1111/j.1600-6143.2006.01643.x
48. Hong ZF, Huang XJ, Yin ZY, Zhao WX, Wang XM. Immunosuppressive function of bone marrow mesenchymal stem cells on acute rejection of liver allografts in rats. Transplant Proc (2009) 41:403-9. doi:10.1016/j.transproceed.2008.10.020
49. Popp FC, Renner P, Eggenhofer E, Slowik P, Geissler EK, Piso P, et al. Mesenchymal stem cells as immunomodulators after liver transplantation. Liver Transpl (2009) 15:1192-8. doi:10.1002/lt.21862
50. Crop MJ, Baan CC, Korevaar SS, Ijzermans JN, Weimar W, Hoogduijn MJ. Human adipose tissue-derived mesenchymal stem cells induce explosive T-cell proliferation. Stem Cells Dev (2010) 19:1843-53. doi:10.1089/scd.2009.0368
51. Di Ianni M, Del Papa B, De Ioanni M, Moretti L, Bonifacio E, Cecchini D, et al. Mesenchymal cells recruit and regulate T regulatory cells. Exp Hematol (2008) 36:309-18. doi:10.1016/j.exphem.2007.11.007
52. Duffy MM, Ritter T, Ceredig R, Griffin MD. Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Res Ther (2011) 2:34. doi:10.1186/scrt75
53. Casiraghi F, Azzollini N, Todeschini M, Cavinato RA, Cassis P, Solini S, et al. Localization of mesenchymal stromal cells dictates their immune or proinflammatory effects in kidney transplantation. Am J Transplant (2012) 12:2373-83. doi:10.1111/j.1600-6143.2012.04115.x
54. De Girolamo L, Lucarelli E, Alessandri G, Avanzini MA, Bernardo ME, Biagi E, et al. Mesenchymal stem/stromal cells: a new "cells as drugs" paradigm. Efficacy and critical aspects in cell therapy. Curr Pharm Des (2013) 19:2459-73. doi:10.2174/1381612811319130015
55. Tan J, Wu W, Xu X, Liao L, Zheng F, Messinger S, et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA (2012) 307:1169-77. doi:10.1001/jama.2012.316
56. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet (2008) 371:1579-86. doi:10.1016/S0140-6736(08)60690-X
57. Kuo YR, Chen CC, Goto S, Lee IT, Huang CW, Tsai CC, et al. Modulation of immune response and T-cell regulation by donor adipose-derived stem cells in a rodent hind-limb allotransplant model. Plast Reconstr Surg (2011) 128:661e-72. doi:10.1097/PRS.0b013e318230c60b
58. Kuo YR, Goto S, Shih HS, Wang FS, Lin CC, Wang CT, et al. Mesenchymal stem cells prolong composite tissue allotransplant survival in a swine model. Transplantation (2009) 87:1769-77. doi:10.1097/TP.0b013e3181a664f1
59. Pan H, Zhao K, Wang L, Zheng Y, Zhang G, Mai H, et al. Mesenchymal stem cells enhance the induction of mixed chimerism and tolerance to rat hind-limb allografts after bone marrow transplantation. J Surg Res (2010) 160:315-24. doi:10.1016/j.jss.2008.09.027
60. Bernardo ME, Fibbe WE. Safety and efficacy of mesenchymal stromal cell therapy in autoimmune disorders. Ann N Y Acad Sci (2012) 1266:107-17. doi:10.1111/j.1749-6632.2012.06667.x
61. Figueroa FE, Carrion F, Villanueva S, Khoury M. Mesenchymal stem cell treatment for autoimmune diseases: a critical review. Biol Res (2012) 45:269-77. doi:10.1590/S0716-97602012000300008
62. Lawitschka A, Ball L, Peters C. Nonpharmacologic treatment of chronic graft-versus-host disease in children and adolescents. Biol Blood Marrow Transplant (2012) 18:S74-81. doi:10.1016/j.bbmt.2011.11.001
63. Casiraghi F, Azzollini N, Cassis P, Imberti B, Morigi M, Cugini D, et al. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol (2008) 181:3933-46.
64. Ge W, Jiang J, Baroja ML, Arp J, Zassoko R, Liu W, et al. Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. Am J Transplant (2009) 9:1760-72. doi:10.1111/j.1600-6143.2009.02721.x
65. Oh JY, Lee RH, Yu JM, Ko JH, Lee HJ, Ko AY, et al. Intravenous mesenchymal stem cells prevented rejection of allogeneic corneal transplants by aborting the early inflammatory response. Mol Ther (2012) 20:2143-52. doi:10.1038/mt.2012.165
66. Hoogduijn MJ, Crop MJ, Korevaar SS, Peeters AM, Eijken M, Maat LP, et al. Susceptibility of human mesenchymal stem cells to tacrolimus, mycophenolic acid, and rapamycin. Transplantation (2008) 86:1283-91. doi:10.1097/TP.0b013e31818aa536
67. Isomoto S, Hattori K, Ohgushi H, Nakajima H, Tanaka Y, Takakura Y. Rapamycin as an inhibitor of osteogenic differentiation in bone marrow-derived mesenchymal stem cells. J Orthop Sci (2007) 12:83-8. doi:10.1007/s00776-006-1079-9
68. Buron F, Perrin H, Malcus C, Hequet O, Thaunat O, Kholopp-Sarda MN, et al. Human mesenchymal stem cells and immunosuppressive drug interactions in allogeneic responses: an in vitro study using human cells. Transplant Proc (2009) 41:3347-52. doi:10.1016/j.transproceed.2009.08.030
69. Eggenhofer E, Steinmann JF, Renner P, Slowik P, Piso P, Geissler EK, et al. Mesenchymal stem cells together with mycophenolate mofetil inhibit antigen presenting cell and T cell infiltration into allogeneic heart grafts. Transpl Immunol (2011) 24:157-63. doi:10.1016/j.trim.2010.12.002
70. Eggenhofer E, Renner P, Soeder Y, Popp FC, Hoogduijn MJ, Geissler EK, et al. Features of synergism between mesenchymal stem cells and immunosuppressive drugs in a murine heart transplantation model. Transpl Immunol (2011) 25:141-7. doi:10.1016/j.trim.2011.06.002
71. Aksu AE, Horibe E, Sacks J, Ikeguchi R, Breitinger J, Scozio M, et al. Co-infusion of donor bone marrow with host mesenchymal stem cells treats GVHD and promotes vascularized skin allograft survival in rats. Clin Immunol (2008) 127:348-58. doi:10.1016/j.clim.2008.02.003
72. Eggenhofer E, Benseler V, Kroemer A, Popp FC, Geissler EK, Schlitt HJ, et al. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol (2012) 3:297. doi:10.3389/fimmu.2012.00297
73. Gao J, Dennis JE, Muzic RF, Lundberg M, Caplan AI. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs (2001) 169:12-20. doi:10.1159/000047856
74. Schrepfer S, Deuse T, Reichenspurner H, Fischbein MP, Robbins RC, Pelletier MP. Stem cell transplantation: the lung barrier. Transplant Proc (2007) 39:573-6. doi:10.1016/j.transproceed.2006.12.019
75. Fischer UM, Harting MT, Jimenez F, Monzon-Posadas WO, Xue H, Savitz SI, et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev (2009) 18:683-92. doi:10.1089/scd.2008.0253
76. Rombouts WJ, Ploemacher RE. Primary murine MSC show highly efficient homing to the bone marrow but lose homing ability following culture. Leukemia (2003) 17:160-70. doi:10.1038/sj.leu.2402763
77. Schlosser S, Dennler C, Schweizer R, Eberli D, Stein JV, Enzmann V, et al. Paracrine effects of mesenchymal stem cells enhance vascular regeneration in ischemic murine skin. Microvasc Res (2012) 83:267-75. doi:10.1016/j.mvr.2012.02.011
78. Karp JM, Leng Teo GS. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell (2009) 4:206-16. doi:10.1016/j.stem.2009.02.001
79. Wagner W, Horn P, Castoldi M, Diehlmann A, Bork S, Saffrich R, et al. Replicative senescence of mesenchymal stem cells: a continuous and organized process. PLoS ONE (2008) 3:e2213. doi:10.1371/journal.pone.0002213
80. Hematti P. Mesenchymal stromal cells and fibroblasts: a case of mistaken identity? Cytotherapy (2012) 14: 516-21. doi:10.3109/14653249.2012.677822
81. Wynn RF, Hart CA, Corradi-Perini C, O'Neill L, Evans CA, Wraith JE, et al. A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood (2004) 104: 2643-5. doi:10.1182/blood-2004-02-0526
82. Ruster B, Gottig S, Ludwig RJ, Bistrian R, Muller S, Seifried E, et al. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood (2006) 108:3938-44. doi:10.1182/blood-2006-05-025098
83. Phinney DG, Prockop DJ. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair - current views. Stem Cells (2007) 25:2896-902. doi:10.1634/stemcells.2007-0637
84. Sackstein R, Merzaban JS, Cain DW, Dagia NM, Spencer JA, Lin CP, et al. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med (2008) 14:181-7. doi:10.1038/nm1703
85. Vacanti V, Kong E, Suzuki G, Sato K, Canty JM, Lee T. Phenotypic changes of adult porcine mesenchymal stem cells induced by prolonged passaging in culture. J Cell Physiol (2005) 205:194-201. doi:10.1002/jcp.20376
86. Wagner W, Ho AD, Zenke M. Different facets of aging in human mesenchymal stem cells. Tissue Eng Part B Rev (2010) 16:445-53. doi:10.1089/ten. TEB.2009.0825
87. Kuo YR, Chen CC, Shih HS, Goto S, Huang CW, Wang CT, et al. Prolongation of composite tissue allotransplant survival by treatment with bone marrow mesenchymal stem cells is correlated with T-cell regulation in a swine hind-limb model. Plast Reconstr Surg (2011) 127:569-79. doi:10.1097/PRS.0b013e318200a92c
88. Kuo YR, Chen CC, Goto S, Huang YT, Wang CT, Tsai CC, et al. Immunomodulatory effects of bone marrow-derived mesenchymal stem cells in a swine hemi-facial allotransplantation model. PLoS ONE (2012) 7:e35459. doi:10.1371/journal.pone.0035459
89. Schneeberger S, Gorantla VS, Brandacher G, Zeevi A, Demetris AJ, Lunz JG, et al. Upper-extremity transplantation using a cell-based protocol to minimize immunosuppression. Ann Surg (2013) 257:345-51. doi:10.1097/SLA.0b013e31826d90bb